Abstract
The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Current Pharmaceutical Design
Title:Why do Psychotic Patients use Cannabis? Case Series
Volume: 18 Issue: 32
Author(s): Anna Kolliakou, Khalida Ismail and Zerrin Atakan
Affiliation:
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Abstract: The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Export Options
About this article
Cite this article as:
Kolliakou Anna, Ismail Khalida and Atakan Zerrin, Why do Psychotic Patients use Cannabis? Case Series, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884807
DOI https://dx.doi.org/10.2174/138161212802884807 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dopamine Agonists in the Treatment of Parkinsons Disease-Past, Present and Future
Current Pharmaceutical Design Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design Pharmacological Therapy of Cushings Syndrome: Drugs and Indications
Mini-Reviews in Medicinal Chemistry Dampening the Progression of Dementia
Current Neurovascular Research Genetic Algorithm and Self-Organizing Maps for QSPR Study of Some N-aryl Derivatives as Butyrylcholinesterase Inhibitors
Current Drug Discovery Technologies Detection, Identification and Structural Elucidation of Flavonoids using Liquid Chromatography Coupled to Mass Spectrometry
Current Organic Chemistry Mephedrone Concentrations in Cases of Clinical Intoxication
Current Pharmaceutical Design Pentosidine, an Advanced Glycation Endproduct, and Arthritis
Current Rheumatology Reviews High Throughput Sonication: Evaluation for Compound Solubilization
Combinatorial Chemistry & High Throughput Screening Psychomotor Seizure Test, Neurotoxicity and in vitro Neuroprotection Assay of some Semicarbazone Analogues
Central Nervous System Agents in Medicinal Chemistry Dehydroepiandrosterone (DHEA): A Steroid with Multiple Effects. Is there Any Possible Option in the Treatment of Critical illness?
Current Medicinal Chemistry Arylglyoxals as Versatile Synthons for Heterocycles Through Multi-Component Reactions
Current Organic Chemistry Molecular Mechanisms of Anti-cancer Action of Garlic Compounds in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Efficacy of the Newest COX-2 Selective Inhibitors in Rheumatic Disease
Current Pharmaceutical Design The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management
Current Drug Safety Multipotent, Permeable Drug ASS234 Inhibits Aβ Aggregation, Possesses Antioxidant Properties and Protects from Aβ-induced Apoptosis In Vitro
Current Alzheimer Research Acid-Sensing Ion Channels Structural Aspects, Pathophysiological Importance and Experimental Mutational Data Available Across Various Species to Target Human ASIC1
Current Drug Targets Long-Term Benzodiazepine Use and Mortality: Are we Doing the Right Studies?
Current Drug Safety Mitochondria Play a Central Role in Estrogen-Induced Neuroprotection
Current Drug Targets - CNS & Neurological Disorders